Work

Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: real-world efficacy and risks of early ponatinib dose reduction

Year: 2026

Type: article

Abstract: Not available.

Source: Haematologica

DOI: 10.3324/haematol.2025.300099

Authors: Jae-Ho Yoon, Kyoung Il Min, Daehun Kwag, Gi-June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Seok Lee

Institutions: The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Ewha Womans University, Ewha Womans University Mokdong Hospital

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,157

Funder: Pfizer

OpenAlex ID: W7126059847

FWCI:

Cites:

Cited by:

Related to: